“Changes in the concentration of EGFR-mutated plasma DNA in the first hours of anti-EGFR therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer” (2021) Voprosy onkologii, 67(5), pp. 665–674. doi:10.37469/0507-3758-2021-67-5-665-674.